Use of methotrexate in the management of recurrent Tolosa-Hunt syndrome: Two case reports. Issue 17 (April 2020)

• Record Type: Journal Article
• Authors: Kwon, Hyuk Sung; Kim, Tae Yoon; Kim, Ji Hyun; Bae, Jeong Hoon; Koh, Seong-Ho; Choi, Hojin; Lee, Kyu-Yong; Lee, Young Joo; Kim, Young Seo; Kim, Hyun Young
• Other Names: NA. section editor.
• Is Part Of: Medicine. Volume 99:Issue 17(2020)
• Publication Date: 2020-04
• Subjects: methotrexate -- prognosis -- Tolosa-Hunt syndrome -- treatment; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000019882
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Tolosa-Hunt syndrome (THS) is rare condition characterized by painful ophthalmoplegia that usually responds well to corticosteroid. About a half of THS patients experience recurrence within intervals of months to years from initial presentation. Recurrence is more common in younger patients, and can be ipsilateral, contralateral, or bilateral. Cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, infliximab, and radiotherapy can be considered as second-line treatment. However, there is insufficient evidence for treatments preventing recurrence of THS. Patient concerns: We experienced two patients with THS that recurred twice while tapering or after ceasing corticosteroid administration. Diagnosis: Both patients were diagnosed as recurrent THS. Interventions: Methotrexate was treated with a combination of corticosteroid after THS recurred twice with corticosteroid therapy alone. Outcomes: After adding methotrexate to the steroid regimen, their symptoms were successfully regulated and ceased to recur Lessons: These cases add to the evidence for the use of methotrexate as a second-line therapeutic agent for those patients with recurrent THS attacks. Further studies are in need to prove the risk and benefits of second-line treatments in THS.